The clinical course in patients with prostate cancer (PCa) after biochemical failure (BF) has received limited attention. This study analyzes survival time from recurrence, patterns of progression, and the efficacy of salvage therapies in patients treated with radical or postoperative radiotherapy (RT).
This is a multicenter retrospective comparative study of 1135 patients diagnosed with BF and treated with either radical (882) or postoperative (253) RT. Data correspond to the RECAP database. Clinical, tumor, and therapeutic characteristics were collected. Descriptive statistics, survival estimates, and comparisons of survival rates were calculated.
Time to BF from initial treatment (RT or surgery) was higher in irradiated patients (51 vs 37 months). At a median follow-up of 102 months (14–254), the 8-year cause-specific survival (CSS) was 80.5%, without significant differences between the radical (80.1%) and postoperative (83.4%) RT groups. The 8-year metastasis-free survival rate was 57%. 173 patients (15%) died of PCa and 29 (2.5%) of a second cancer. No salvage therapy was given in 15% of pts. Only 5.5% of pts who underwent radical RT had local salvage treatment and 71% received androgen deprivation (AD) ± chemotherapy. The worst outcomes were in patients who developed metastases after BF (302 pts; 26.5%) and in cases with a Gleason > 7.
In PCa treated with radiotherapy, median survival after BF is relatively long. In this sample, no differences in survival rates at 8-years have been found, regardless of the time of radiotherapy administered. AD was the most common treatment after BF. Metastases and high Gleason score are adverse variables. To our knowledge, this is the first study to compare outcomes after BF among patients treated with primary RT vs. those treated with postoperative RT and to evaluate recurrence patterns, treatments administered, and causes of death. The results allow avoiding overtreatment, improving quality of life, without negatively affecting survival.
This is a preview of subscription content, log in to check access.
Buy single article
Instant access to the full article PDF.
Price includes VAT for USA
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
This is the net price. Taxes to be calculated in checkout.
Galceran J, Ameijide A, Carulla M, Mateos A, Quirós JR, Rojas D, et al. Cancer incidence in Spain, 2015. Clin Transl Oncol. 2017;19:799–825.
Vassil AD, Murphy ES, Reddy CA, Angermeier KW, Altman A, Chehade N, et al. Five-year biochemical recurrence free survival for intermediate risk prostate cancer after radical prostatectomy, external beam radiation therapy or permanent seed implantation. Urology. 2010;76:1251–7.
McMullen AW. A structured literature review to determine the use of de American Society for Therapeutic Radiology and Oncology consensus definition of biochemical failure. Urology. 2003;61(2):391–6.
Suardi N, Reuther CR, Walz J, Kodama K, Gibbons RP, Correa R, et al. A nomogram predicting long-term biochemical recurrence after radical prostatectomy. Cancer. 2008;112:1254–63.
D’Amico AV, Whittington R, Malkowicz SB, Cote K, Loffredo M, Schultz D, et al. Biochemical outcome after radical prostatectomy or external beam radiation therapy for patients with clinically localized prostate carcinoma in the prostate specific antigen era. Cancer. 2002;95:281–6.
González-San Segundo C, Herranz F, Álvarez A, Cuesta P, Gómez M, Paños E, Santos JA. Radical prostatectomy versus external-beam radiotherapy for localized prostate cancer: long-term effect on biochemical control. In search of the optimal treatment. Ann Surg Oncol. 2011;18:2980–7. https://doi.org/10.1245/s10434-011-1660-0.
Roach M, Hanks G, Thames H Jr, et al. Defining Biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys. 2006;65(4):965–74.
Cookson MS, Aus G, Burnett AL, Cinby-Hagino ED, D’Amico AV, Dmochowski RR, et al. Variation in the definition el biochemical recurrence in patients treated for localized prostate cancer: the American Urological Association prostate guidelines for localized prostate cancer update panel report and recommendations for a standard in the reporting of surgical outcomes. J Urol. 2007;177:540–5.
Stephenson AJ, Shariat SF, Zelefsky MJ, Kattan MW, Butler EB, et al. Salvage radiotherapy for recurrent prostate cancer after radical prostatectomy. JAMA. 2004;291:1325–32.
Koppie TM, Grossfeld GD, Nudell DM, Weinberg VK, Carroll PR. Is anastomotic biopsy necessary before radiotherapy after radical prostatectomy? J Urol. 2001;166:111–5.
NCCN clinical practice guidelines in prostate cancer, Version 2.2017; 2017. https://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf. Accessed Oct 2017.
Nguyen PL, D’Amico AV, Lee AK, Suh WW. Patient selection, cancer control, and complications after salvage local therapy for postradiation prostate-specific antigen failure: a systematic review of the literature. Cancer. 2007;110:1417–28.
Breeuwsma AJ, Pruim J, van den Bergh AC, et al. Detection of local, regional, and distant recurrence in patients with PSA relapse after external-beam radiotherapy using (11)C-choline positron emission tomography. Int J Radiat Oncol Biol Phys. 2010;77:160–4.
Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, Van der Kwast T, et al. EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol. 2014;65:467–79.
Crook JM, O’Callaghan CJ, Duncan G, Dearnaley DP, Higano CS, Horwitz EM, et al. Intermittent androgen suppression for rising PSA level after radiotherapy. N Eng J Med. 2012;367:895–903.
Hussain M, Tangen CM, Berry DL, Higano CS, Crawford ED, Liu G, et al. Intermittent versus Continuous Androgen Deprivation in Prostate Cancer. N Eng J Med. 2013;368:1314–25.
Arvold ND, Chen MH, Moul JW, Moran BJ, Dosoretz DE, Bañez LL, et al. Risk of death from prostate cancer after radical prostatectomy or brachytherapy in men with low or intermediate risk disease. J Urol. 2011;186:91–6.
Abdollah F, Boorjian SA, Cozzarini C, Suardi N, Sun M, Fiorino C, et al. Survival following biochemical recurrence after radical prostatectomy and adjuvant radiotherapy in patients with prostate cancer: the impact of competing causes of mortality and patient stratification. Eur Cancer. 2013;64(4):557–64.
Boorjian SA, Tollefson MK, Houston Thompson R, Rangel LJ, Bergstralh EJ, Karnes RG. Natural history of biochemical recurrence after radical prostatectomy with adjuvant radiation therapy. J Urol. 2012;188:1761–6.
Lee BH, Kibel AS, Ciezki JP, Klein EA, Reddy CA, Yu C, et al. Are biochemical recurrence outcomes similar after radical prostatectomy and radiation therapy? Analysis of prostate cancer-specific mortality by nomogram-predicted risks of biochemical recurrence. Eur Urol. 2015;67:204–9.
López Torrecilla J, Hervás A, Zapatero A, Gómez Caamaño A, Macías V, Herruzo I, et al. Uroncor consensus statement: management of biochemical recurrence after radiotherapy for prostate cancer: from biochemical failure to castration resistance. Rep Pract Oncol Radiot. 2015;20:259–72.
Chade DC, Shariat SF, Cronin AM, Savage CJ, Jeffrey Karnes R, Blute ML, et al. Salvage radical prostatectomy for radiation-recurrent prostate cancer: a multi-institutional collaboration. Eur Urol. 2011;60:205–10.
Zelefsky MJ, Ben-Porat L, Scher HI, Chan HM, Fearn PA, Fuks ZY, et al. Outcome predictors for the increasing PSA state after definitive external-beam radiotherapy for prostate cancer. J Clin Oncol. 2005;23:826–31.
Nepple KG, Stephenson AJ, Kallogjeri D, Michlaski J, Grubb RL 3rd, Strope SA, et al. Mortality after prostate cancer treatment with radical prostatectomy, external-beam radiation therapy or brachytherapy in men without comorbidity. Eur Urol. 2013;64:372–8.
Shao YH, Kim S, Moore DF, Shih W, Lin Y, Stein M, et al. Cancer-specific survival after metastasis following primary prostatectomy compared with radiation therapy in prostate cancer patients: results of a population-based, propensity score-matched analysis. Eur Urol. 2014;65:693–700.
Razek AAKA, Shamaa S, Lattif MA, Yousef HH. Inter-observer agreement of whole-body computed tomography in staging and response assessment in lymphoma: the Lugano classification. Pol J Radiol. 2017;82:441–7.
Razek AA, Ezzat A, Azmy E, Tharwat N. Role of whole-body 64-slice multidetector computed tomography in treatment planning for multiple myeloma. Radiol Med. 2013;118:799–805.
Wu LM, Xu JR, Gu HY, Hua J, Zhu J, Chen J, et al. Role of magnetic resonance imaging in the detection of local prostate cancer recurrence after external beam radiotherapy and radical prostatectomy. Clin Oncol. 2013;25:252–64.
Panebianco V, Sciarra A, Lisi D, Galati F, Buonocore V, Catalano C, et al. Prostate cancer: 1HMRS-DCEMR at 3T versus [(18)F] choline PET/TC in the detection of local prostate recurrence in men with biochemical progression after radical retropubic prostatectomy (RRP). Eur J Radiol. 2012;81:700–8.
Suardi N, Gandaglia G, Gallina A, Di Trapani E, Scattoni V, Vizziello D, et al. Long-term outcomes of salvage lymph node dissection for clinically recurrent prostate cancer: results of a single-institution series with a minimum follow-up of 5 years. Eur Urol. 2015;67:299–309.
Tilki D, Mandel P, Seeliger F, Kretschmer A, Karl A, Ergün S, et al. Salvage lymph node dissection for nodal recurrence of prostate cancer after radical prostatectomy. J Urol. 2015;193:484–90.
Zumsteg ZS, Spratt DE, Romesser PB, Pei X, Zhang Z, Kollmeier M, et al. Anatomical patterns of recurrence following biochemical relapse in the dose escalation era of external beam radiotherapy for prostate cancer. J Urol. 2015;194:1624–30.
Moghanaki D, Koontz BF, Karlin JD, Wan W, Mukhopadhay N, Hagan M, Anscher MS. Elective irradiation of pelvic lymph nodes during postprostatectomy salvage radiotherapy. Cancer. 2013;119:52–60.
Spiotto MT, Hancock SL, King CR. Radiotherapy after prostatectomy: improved biochemical relapse-free survival with whole pelvic compared with prostate bed only for high-risk patients. Int J Radiat Oncol Biol Phys. 2007;69:54–61.
Kim BS, Lashkari A, Vongtama R, Lee SP, Parker RG. Effect of pelvic lymph node irradiation in salvage therapy for patients with prostate cancer with a biochemical relapse following radical prostatectomy. Clin Prostate Cancer. 2004;3:93–7.
Boukaram C, Hannoun-Levi JM. Management of prostate cancer recurrence after definitive radiation therapy. Cancer Treat Rev. 2010;36:91–100.
Cary KC, Paciorek A, Fuldeore MJ, Carroll PR, Cooperberg MR. Temporal trends and predictors of salvage cancer treatment after failure following radical prostatectomy or radiation therapy. Cancer. 2014;120:507–12.
Huang WC, Kuroiwa K, Serio AM, Bianco FJ, Fine SW, Shayegan B, et al. The anatomical and pathological characteristics of irradiated prostate cancers may influence the oncologycal efficacy of salvage ablative therapies. J Urol. 2007;177:1324–9.
Prada PJ, Jiménez I, González-Suárez H, Fernández J, Cuervo-Arango C, Méndez L. High-dose-rate interstitial brachytherapy as monotherapy in one fraction and transperineal hyaluronic acid injection into the perirectal fat for the treatment of favorable stage prostate cancer: treatment description and preliminary results. Brachytherapy. 2012;11:105–10.
Shipley WU, Seiferheld W, Lukka HR, Major PP, Heney NM, Grignon DJ, et al. Radiation with or without antiandrogen therapy in recurrent prostate cancer. N Eng J Med. 2017;376:417–28.
Carrie C, Hasbini A, De Laroche G, Richaud P, Guerif S, Latorzeff I, et al. Salvage radiotherapy with or without short-term hormone therapy for rising prostate-specific antigen concentration after radical prostatectomy (GETUG-AFU 16): a randomized, multicentre, open-label phase 3. Lancet Oncol. 2016;17:747–56.
Van den Broek T, Van den Bergh RCN, Arfi N, Gross T, Moris L, Briers E, et al. Prognostic value of biochemical recurrence following treatment with curative intent for prostate cancer: a systematic review. Eur Urol. 2018. https://doi.org/10.1016/j.eururo.2018.10.011.
Conflict of interest
The authors declare that they have no conflict of interest.
This article does not contain any experimental studies with human participants or animals performed by any of the authors. The clinical data review was approved by the Clinical Research Ethics Committees at each centre.
For this type of study formal consent is not required.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
González-San Segundo, C., Jové, J., Zapatero, A. et al. Survival after biochemical failure in prostate cancer treated with radiotherapy: Spanish Registry of Prostate Cancer (RECAP) database outcomes. Clin Transl Oncol 21, 1044–1051 (2019). https://doi.org/10.1007/s12094-018-02021-7
- Prostate cancer
- Biochemical failure
- Survival rate
- Salvage therapy